{"id":"diltiazem-and-acetylcystein","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache (diltiazem)"},{"rate":null,"effect":"Dizziness (diltiazem)"},{"rate":null,"effect":"Constipation (diltiazem)"},{"rate":null,"effect":"Nausea (acetylcysteine)"},{"rate":null,"effect":"Rash (acetylcysteine)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Diltiazem is a non-dihydropyridine calcium channel blocker that decreases intracellular calcium, reducing cardiac contractility and heart rate, commonly used for arrhythmias and angina. Acetylcysteine is a thiol-containing antioxidant that replenishes glutathione stores and scavenges reactive oxygen species, potentially protecting tissues from oxidative stress and drug toxicity. The combination may be investigated for cardioprotection or to mitigate diltiazem-related adverse effects in specific cardiac conditions.","oneSentence":"This combination uses diltiazem to reduce calcium influx and improve cardiac function while acetylcysteine provides antioxidant and mucolytic support to protect against drug-induced injury.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:31.113Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Investigational combination therapy in phase 3 (specific indication not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT01771978","phase":"PHASE3","title":"Ischaemia-réperfusion During the Coronary Surgery With Beating Heart","status":"UNKNOWN","sponsor":"University Hospital, Strasbourg, France","startDate":"2002-06","conditions":"Ischaemia-reperfusion Injury","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Combined diltiazem and acetylcystein drug group"],"phase":"phase_3","status":"active","brandName":"diltiazem and acetylcystein","genericName":"diltiazem and acetylcystein","companyName":"University Hospital, Strasbourg, France","companyId":"university-hospital-strasbourg-france","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses diltiazem to reduce calcium influx and improve cardiac function while acetylcysteine provides antioxidant and mucolytic support to protect against drug-induced injury. Used for Investigational combination therapy in phase 3 (specific indication not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}